Aerie Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Aerie Pharmaceuticals is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension.
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Aerie Pharmaceuticals balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Aerie Pharmaceuticals cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Aerie Pharmaceuticals multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Aerie Pharmaceuticals profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Aerie Pharmaceuticals assets
Aerie Pharmaceuticals cash flows
Aerie Pharmaceuticals news
22.11.2022
Alcon completed its acquisition of Aerie Pharmaceuticals for $770 million, or 15.25 per share.
Source: {source} pictogram investor.alcon.com
Pictogram next
23.08.2022
Alcon is buying Aerie Pharmaceuticals for $770 million, or 15.25 per share. Deal is scheduled to close in the fourth quarter of 2022.
Source: {source} pictogram investor.alcon.com
Pictogram next
05.05.2022
The loss of Aerie Pharmaceuticals under GAAP for the 3 months of 2022 was $35.891 million, down 14.5% compared to $41.964 million in the previous year. Revenue increased 29.9% to $29.835 million from $22.97 million a year earlier.
Source: {source} pictogram investors.aeriepharma.com
Pictogram next
25.02.2022
Aerie Pharmaceuticals' GAAP net income for 2021 was $74.81 million, down 59.1% from $183.101 million in the previous year. Revenue increased 2.3 times to $194.134 million from $83.138 million a year earlier.
Source: {source} pictogram investors.aeriepharma.com
Pictogram next
All Aerie Pharmaceuticals news
General information
Company nameAerie Pharmaceuticals
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300
Mailing address4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703
Websiteaeriepharma.com